Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Phoenix Children's Hospital Fisher Bioservices EUSA Pharma (US), Inc. |
---|---|
Information provided by: | Phoenix Children's Hospital |
ClinicalTrials.gov Identifier: | NCT00590915 |
The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.
Condition | Intervention |
---|---|
Leukemia, Acute Lymphoblastic Acute Lymphoid Leukemia |
Drug: Erwinia L-asparaginase |
Study Type: | Expanded Access |
Official Title: | Erwinase Master Treatment Protocol |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contact: Paul Plourde, MD | 215-230-9622 | Paul.Plourde@eusapharma.com |
Responsible Party: | Phoenix Children's Hospital ( Jessica Boklan, MD/Director, Oncology Research ) |
Study ID Numbers: | Erwinase, IND-290 |
Study First Received: | December 26, 2007 |
Last Updated: | April 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00590915 History of Changes |
Health Authority: | United States: Food and Drug Administration |
ALL |
Asparaginase Pegaspargase Lymphatic Diseases Leukemia Leukemia, Lymphoid |
Immunoproliferative Disorders Precursor Cell Lymphoblastic Leukemia-Lymphoma Lymphoproliferative Disorders Lymphoma Acute Lymphoblastic Leukemia |
Asparaginase Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents |
Pharmacologic Actions Leukemia Lymphatic Diseases Neoplasms Therapeutic Uses Lymphoproliferative Disorders |